DNA241220C4000
- 4.35
- 0.000.00%
Ginkgo Bioworks Newsroom
Morgan Stanley Maintains Ginkgo Bioworks(DNA.US) With Hold Rating, Maintains Target Price $10
Morgan Stanley Maintains Ginkgo Bioworks(DNA.US) With Hold Rating, Maintains Target Price $10
BTIG Maintains Ginkgo Bioworks(DNA.US) With Sell Rating, Cuts Target Price to $6
TD Cowen Maintains Ginkgo Bioworks(DNA.US) With Buy Rating, Maintains Target Price $10
Positive Outlook for Ginkgo Bioworks: Strategic Developments and Financial Strength Bolster Buy Rating
Morgan Stanley Maintains Ginkgo Bioworks(DNA.US) With Hold Rating, Cuts Target Price to $10
TD Cowen Maintains Ginkgo Bioworks(DNA.US) With Buy Rating, Maintains Target Price $10
TD Cowen Initiates Ginkgo Bioworks(DNA.US) With Buy Rating, Announces Target Price $10
Ginkgo Bioworks Holdings: A Buy Rating on Strategic AI Advancements and Market Expansion
BTIG Maintains Ginkgo Bioworks(DNA.US) With Sell Rating, Maintains Target Price $7
Ginkgo Bioworks Holdings Analyst Ratings
BTIG Maintains Ginkgo Bioworks(DNA.US) With Sell Rating, Cuts Target Price to $7
Ginkgo Bioworks Holdings: Sell Rating Affirmed With Revised Valuation and Price Target
Morgan Stanley Maintains Ginkgo Bioworks(DNA.US) With Hold Rating, Maintains Target Price $40
Analysts Offer Insights on Healthcare Companies: Ginkgo Bioworks Holdings (DNA) and LifeMD (LFMD)
Ginkgo Bioworks: Hold Rating Maintained Amid Revenue Uncertainty and Restructuring Challenges
Ginkgo Bioworks: Underperform Rating Due to Financial Strain and Uncertain Strategic Outcomes
Ginkgo Bioworks Holdings Analyst Ratings
Ginkgo Bioworks Holdings Analyst Ratings
Ginkgo Bioworks Holdings Analyst Ratings